
List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/6590894/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	Clinical features and prognosis of Miller Fisher syndrome. Neurology, 2001, 56, 1104-1106.	1.5	365
2	Axonal Guillain-Barr� syndrome: Relation to anti-ganglioside antibodies andCampylobacter jejuni infection in Japan. Annals of Neurology, 2000, 48, 624-631.	2.8	308
3	Cytokine and chemokine profiles in neuromyelitis optica: significance of interleukin-6. Multiple Sclerosis Journal, 2010, 16, 1443-1452.	1.4	285
4	Safety and efficacy of rituximab in neuromyelitis optica spectrum disorders (RIN-1 study): a multicentre, randomised, double-blind, placebo-controlled trial. Lancet Neurology, The, 2020, 19, 298-306.	4.9	218
5	Diagnosis and Treatment of NMO Spectrum Disorder and MOG-Encephalomyelitis. Frontiers in Neurology, 2018, 9, 888.	1.1	194
6	Subcutaneous immunoglobulin for maintenance treatment in chronic inflammatory demyelinating polyneuropathy (PATH): a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet Neurology, The, 2018, 17, 35-46.	4.9	193
7	Intravenous immunoglobulin therapy for Miller Fisher syndrome. Neurology, 2007, 68, 1144-1146.	1.5	128
8	Markedly increased CSF interleukin-6 levels in neuromyelitis optica, but not in multiple sclerosis. Journal of Neurology, 2009, 256, 2082-2084.	1.8	104
9	Neuromyelitis optica and anti-aquaporin-4 antibodies measured by an enzyme-linked immunosorbent assay. Journal of Neuroimmunology, 2008, 196, 181-187.	1.1	102
10	Different electrophysiological profiles and treatment response in â€~typical' and â€~atypical' chronic inflammatory demyelinating polyneuropathy. Journal of Neurology, Neurosurgery and Psychiatry, 2015, 86, 1054-1059.	0.9	95
11	Worldwide prevalence of neuromyelitis optica spectrum disorders. Journal of Neurology, Neurosurgery and Psychiatry, 2018, 89, 555-556.	0.9	87
12	Cytokines and Chemokines in Neuromyelitis Optica: Pathogenetic and Therapeutic Implications. Brain Pathology, 2014, 24, 67-73.	2.1	79
13	Special sensory ataxia in Miller Fisher syndrome detected by postural body sway analysis. Annals of Neurology, 1999, 45, 533-536.	2.8	76
14	Cerebrospinal fluid interleukin-6 and glial fibrillary acidic protein levels are increased during initial neuromyelitis optica attacks. Clinica Chimica Acta, 2013, 421, 181-183.	0.5	74
15	Moesin is a possible target molecule for cytomegalovirus-related Guillain-Barré syndrome. Neurology, 2014, 83, 113-117.	1.5	56
16	Fisher syndrome: clinical features, immunopathogenesis and management. Expert Review of Neurotherapeutics, 2012, 12, 39-51.	1.4	55
17	Neuromyelitis optica: Concept, immunology and treatment. Journal of Clinical Neuroscience, 2014, 21, 12-21.	0.8	48
18	Increased cerebrospinal fluid metalloproteinase-2 and interleukin-6 are associated with albumin quotient in neuromyelitis optica: Their possible role on blood–brain barrier disruption. Multiple Sclerosis Journal, 2017, 23, 1072-1084.	1.4	48

#	Article	IF	CITATIONS
19	How often and when Fisher syndrome is overlapped by Guillainâ€Barré syndrome or Bickerstaff brainstem encephalitis?. European Journal of Neurology, 2016, 23, 1058-1063.	1.7	46
20	Intravenous immunoglobulin for maintenance treatment of chronic inflammatory demyelinating polyneuropathy: a multicentre, open-label, 52-week phase III trial. Journal of Neurology, Neurosurgery and Psychiatry, 2017, 88, 832-838.	0.9	45
21	CSF high-mobility group box 1 is associated with intrathecal inflammation and astrocytic damage in neuromyelitis optica. Journal of Neurology, Neurosurgery and Psychiatry, 2013, 84, 517-522.	0.9	44
22	Association of anti-aquaporin-4 antibody-positive neuromyelitis optica with myasthenia gravis. Journal of the Neurological Sciences, 2009, 287, 105-107.	0.3	43
23	Peripheral nerve demyelination in multiple sclerosis. Clinical Neurophysiology, 2008, 119, 1829-1833.	0.7	42
24	Plasmapheresis and Miller Fisher syndrome: analysis of 50 consecutive cases. Journal of Neurology, Neurosurgery and Psychiatry, 2002, 72, 680-680.	0.9	41
25	Serum cytokine and chemokine profiles in patients with chronic inflammatory demyelinating polyneuropathy. Journal of Neuroimmunology, 2015, 279, 7-10.	1.1	40
26	Association of serum levels of antibodies against MMP1, CBX1, and CBX5 with transient ischemic attack and cerebral infarction. Oncotarget, 2018, 9, 5600-5613.	0.8	38
27	Soluble CD40 ligand contributes to blood–brain barrier breakdown and central nervous system inflammation in multiple sclerosis and neuromyelitis optica spectrum disorder. Journal of Neuroimmunology, 2017, 305, 102-107.	1.1	35
28	lgG anti-GQ1b positive acute ataxia without ophthalmoplegia. Journal of Neurology, Neurosurgery and Psychiatry, 1999, 67, 668-670.	0.9	32
29	Interleukin-6 analysis of 572 consecutive CSF samples from neurological disorders: A special focus on neuromyelitis optica. Clinica Chimica Acta, 2017, 469, 144-149.	0.5	32
30	Epstein-Barr virus persistence and reactivation in neuromyelitis optica. Journal of Neurology, Neurosurgery and Psychiatry, 2015, 86, 1137-1142.	0.9	31
31	Serum antinuclear antibody may be associated with less severe disease activity in neuromyelitis optica. European Journal of Neurology, 2016, 23, 276-281.	1.7	30
32	Novel serum autoantibodies against talin1 in multiple sclerosis: Possible pathogenetic roles of the antibodies. Journal of Neuroimmunology, 2015, 284, 30-36.	1.1	28
33	Current symptomatology in multiple sclerosis and neuromyelitis optica. European Journal of Neurology, 2015, 22, 299-304.	1.7	25
34	Efficacy and Safety of Rituximab in Refractory CIDP With or Without IgG4 Autoantibodies (RECIPE): Protocol for a Double-Blind, Randomized, Placebo-Controlled Clinical Trial. JMIR Research Protocols, 2020, 9, e17117.	0.5	23
35	Fisher Syndrome. Current Treatment Options in Neurology, 2011, 13, 71-78.	0.7	22
36	Concomitant chronic inflammatory demyelinating polyneuropathy and myasthenia gravis following cytomegalovirus infection. Journal of the Neurological Sciences, 2006, 240, 103-106.	0.3	20

#	Article	IF	CITATIONS
37	First adult case of Helicobacter cinaedi meningitis. Journal of the Neurological Sciences, 2014, 336, 263-264.	0.3	20
38	The accuracy of flow cytometric cell-based assay to detect anti-myelin oligodendrocyte glycoprotein (MOG) antibodies determining the optimal method for positivity judgement. Journal of Neuroimmunology, 2019, 336, 577021.	1.1	20
39	Peripheral blood helper T cell profiles and their clinical relevance in MOG-IgG-associated and AQP4-IgG-associated disorders and MS. Journal of Neurology, Neurosurgery and Psychiatry, 2020, 91, 132-139.	0.9	20
40	Anti-MOG antibody–associated disorders: differences in clinical profiles and prognosis in Japan and Germany. Journal of Neurology, Neurosurgery and Psychiatry, 2021, 92, 377-383.	0.9	18
41	Novel autoantibodies against the proteasome subunit PSMA7 in amyotrophic lateral sclerosis. Journal of Neuroimmunology, 2018, 325, 54-60.	1.1	17
42	Efficacy and safety of IVIG in CIDP: Combined data of the PRIMA and PATH studies. Journal of the Peripheral Nervous System, 2019, 24, 48-55.	1.4	17
43	Recovery from optic neuritis attack in neuromyelitis optica spectrum disorder and multiple sclerosis. Journal of the Neurological Sciences, 2016, 367, 375-379.	0.3	16
44	Validation of the Brief International Cognitive Assessment for Multiple Sclerosis in Japan. Multiple Sclerosis Journal - Experimental, Translational and Clinical, 2017, 3, 205521731774897.	0.5	16
45	Serum antiâ€LRPAP1 is a common biomarker for digestive organ cancers and atherosclerotic diseases. Cancer Science, 2020, 111, 4453-4464.	1.7	16
46	Serum anti-JCV antibody indexes in Japanese patients with multiple sclerosis: elevations along with fingolimod treatment duration. Journal of Neurology, 2018, 265, 1145-1150.	1.8	15
47	Silent progression of brain atrophy in aquaporin-4 antibody-positive neuromyelitis optica spectrum disorder. Journal of Neurology, Neurosurgery and Psychiatry, 2022, 93, 32-40.	0.9	15
48	Trigeminal root entry zone involvement in neuromyelitis optica and multiple sclerosis. Journal of the Neurological Sciences, 2015, 355, 147-149.	0.3	14
49	Risk factors for fingolimod-induced lymphopenia in multiple sclerosis. Multiple Sclerosis Journal - Experimental, Translational and Clinical, 2018, 4, 205521731875969.	0.5	14
50	Recombinant thrombomodulin ameliorates experimental autoimmune encephalomyelitis by suppressing high mobility group box 1 and inflammatory cytokines. Clinical and Experimental Immunology, 2018, 193, 47-54.	1.1	14
51	Restabilization treatment after intravenous immunoglobulin withdrawal in chronic inflammatory demyelinating polyneuropathy: Results from the preâ€randomization phase of the Polyneuropathy And Treatment with Hizentra study. Journal of the Peripheral Nervous System, 2019, 24, 72-79.	1.4	13
52	Serum anti-DIDO1, anti-CPSF2, and anti-FOXJ2 antibodies as predictive risk markers for acute ischemic stroke. BMC Medicine, 2021, 19, 131.	2.3	13
53	Bickerstaff's brainstem encephalitis after an outbreak of Campylobacter jejuni enteritis. Journal of Neuroimmunology, 2008, 196, 143-146.	1.1	12
54	Detection of mumps virus RNA in cerebrospinal fluid of patients with neuromyelitis optica. Neurological Sciences, 2011, 32, 795-799.	0.9	11

#	Article	IF	CITATIONS
55	Intravenous immunoglobulin for maintenance treatment of multifocal motor neuropathy: A multi enter, openâ€label, 52â€week phase 3 trial. Journal of the Peripheral Nervous System, 2018, 23, 115-119.	. 1.4	11
56	Soluble CD40 ligand disrupts the blood–brain barrier and exacerbates inflammation in experimental autoimmune encephalomyelitis. Journal of Neuroimmunology, 2018, 316, 117-120.	1.1	11
57	Difference in fatigue and pain between neuromyelitis optica spectrum disorder and multiple sclerosis. PLoS ONE, 2020, 15, e0224419.	1.1	11
58	Novel serum autoantibodies against ß-actin (ACTB) in amyotrophic lateral sclerosis. Amyotrophic Lateral Sclerosis and Frontotemporal Degeneration, 2021, 22, 388-394.	1.1	11
59	High levels of serum interleukin-6 are associated with disease activity in myasthenia gravis. Journal of Neuroimmunology, 2021, 358, 577634.	1.1	11
60	Increased levels of CSF CD59 in neuromyelitis optica and multiple sclerosis. Clinica Chimica Acta, 2016, 453, 131-133.	0.5	10
61	Comparison of cognitive and brain grey matter volume profiles between multiple sclerosis and neuromyelitis optica spectrum disorder. PLoS ONE, 2017, 12, e0184012.	1.1	10
62	Validation of the Modified Fatigue Impact Scale and the relationships among fatigue, pain and serum interleukin-6 levels in patients with neuromyelitis optica spectrum disorder. Journal of the Neurological Sciences, 2018, 385, 64-68.	0.3	10
63	Association of cognitive impairment with magnetic resonance imaging findings and social activities in patients with multiple sclerosis. Clinical and Experimental Neuroimmunology, 2014, 5, 328-335.	0.5	9
64	Seronegative neuromyelitis optica spectrum disorder patients diagnosed using new diagnostic criteria. Multiple Sclerosis Journal, 2016, 22, 1371-1375.	1.4	9
65	Nodopathy: chronic inflammatory demyelinating polyneuropathy with anti-neurofascin 155 antibodies. Journal of Neurology, Neurosurgery and Psychiatry, 2017, 88, 459-459.	0.9	9
66	Role of interleukinâ€6 in the pathogenesis of neuromyelitis optica. Clinical and Experimental Neuroimmunology, 2013, 4, 167-172.	0.5	8
67	Urinary symptoms and neurological disabilities are differentially correlated between multiple sclerosis and neuromyelitis optica. Clinical and Experimental Neuroimmunology, 2016, 7, 52-58.	0.5	8
68	Relapse numbers and earlier intervention by disease modifying drugs are related with progression of less brain atrophy in patients with multiple sclerosis. Journal of the Neurological Sciences, 2019, 403, 78-84.	0.3	8
69	Seroconversion of anti-aquaporin-4 antibody in NMO spectrum disorder: a case report. Journal of Neurology, 2012, 259, 980-981.	1.8	6
70	Chronic inflammatory demyelinating polyneuropathy: The spectrum and immunopathogenesis deciphered by electrophysiology and neuroimaging. Clinical and Experimental Neuroimmunology, 2018, 9, 47-53.	0.5	6
71	Peroxiredoxins are involved in the pathogenesis of multiple sclerosis and neuromyelitis optica spectrum disorder. Clinical and Experimental Immunology, 2020, 202, 239-248.	1.1	6
72	Serum Sphingosine 1-Phosphate (S1P): A Novel Diagnostic Biomarker in Early Acute Ischemic Stroke. Frontiers in Neurology, 2020, 11, 985.	1.1	6

#	Article	IF	CITATIONS
73	AQP4-IgG autoimmunity in Japan and Germany: Differences in clinical profiles and prognosis in seropositive neuromyelitis optica spectrum disorders. Multiple Sclerosis Journal - Experimental, Translational and Clinical, 2021, 7, 205521732110068.	0.5	6
74	A patient with neuromyelitis optica with positive anti-Ro (SS-A) antibody presenting with intractable hiccup and nausea. Modern Rheumatology, 2011, 21, 561-562.	0.9	5
75	Is â€~Bickerstaff brainstem encephalitis' really encephalitis?. Journal of Neurology, Neurosurgery and Psychiatry, 2013, 84, 712-712.	0.9	5
76	Are more sphingosine 1-phosphate receptor agonists a better therapeutic option against multiple sclerosis?. Journal of Neurology, Neurosurgery and Psychiatry, 2014, 85, 1180-1180.	0.9	5
77	Lower motor neuron syndrome associated with IgG anti-GM1 antibodies revisited. Journal of Neuroimmunology, 2014, 272, 62-66.	1.1	5
78	Steroid-Responsive Epilepsia Partialis Continua with Anti-Thyroid Antibodies: A Spectrum of Hashimoto's Encephalopathy. Case Reports in Neurology, 2014, 6, 166-170.	0.3	5
79	Validation of the Japanese version of the Modified Fatigue Impact Scale and assessment of the effect of pain on scale responses in patients with multiple sclerosis. Clinical and Experimental Neuroimmunology, 2015, 6, 409-412.	0.5	5
80	Autoantibodies against vinculin in patients with chronic inflammatory demyelinating polyneuropathy. Journal of Neuroimmunology, 2015, 287, 9-15.	1.1	5
81	Serum soluble Talin-1 levels are elevated in patients with multiple sclerosis, reflecting its disease activity. Journal of Neuroimmunology, 2017, 305, 131-134.	1.1	5
82	Identification of Serum Anti-GADD34 Antibody as a Common Marker of Diabetes Mellitus and Parkinson Disease. , 2017, 07, .		5
83	Cognitive Impairment in Multiple System Atrophy Is Related to White Matter Damage Detected by the T1-Weighted/T2-Weighted Ratio. European Neurology, 2021, 84, 435-443.	0.6	5
84	Benign neuromyelitis optica is rare in Japanese patients. Multiple Sclerosis Journal, 2015, 21, 1204-1208.	1.4	4
85	MOG antibody disorders and AQP4 antibody NMO spectrum disorders share a common immunopathogenesis. Journal of Neurology, Neurosurgery and Psychiatry, 2018, 89, 900-900.	0.9	4
86	Atypical chronic inflammatory demyelinating polyneuropathies. Journal of Neurology, Neurosurgery and Psychiatry, 2019, 90, 121-121.	0.9	4
87	Serum anti-John Cunningham virus antibody seroprevalence and index among Japanese patients with neuromyelitis optica spectrum disorders. Multiple Sclerosis Journal, 2020, 26, 128-129.	1.4	4
88	Comparison of brain atrophy in patients with multiple sclerosis treated with first†versus secondâ€generation disease modifying therapy without clinical relapse. European Journal of Neurology, 2020, 27, 2056-2061.	1.7	4
89	Cultural bias in motor function patterns: Potential relevance for predictive, preventive, and personalized medicine. EPMA Journal, 2021, 12, 91-101.	3.3	4
90	Complete Relief of Painful Tonic Seizures in Neuromyelitis Optica Spectrum Disorder by Satralizumab Treatment. Internal Medicine, 2022, 61, 2785-2787.	0.3	4

#	Article	IF	CITATIONS
91	Change in vital signs after fingolimod initiation in patients with multiple sclerosis: the possible need for 24 h monitoring. British Journal of Clinical Pharmacology, 2015, 80, 607-608.	1.1	3
92	Paranodal destruction and axo-glial dysjunction in a subtype of CIDP with anticontaction-1 antibodies. Journal of Neurology, Neurosurgery and Psychiatry, 2015, 86, 707-707.	0.9	3
93	Serum cytokine and chemokine profiles in patients with juvenile muscular atrophy of distal upper extremity (Hirayama disease). Journal of Neuroimmunology, 2017, 302, 20-22.	1.1	3
94	Different patterns of brainstem and cerebellar MRI abnormalities in demyelinating disorders with MOG and aquaporin-4 antibodies. Journal of Neurology, Neurosurgery and Psychiatry, 2021, 92, 348-348.	0.9	3
95	Dementia and Parkinson-like syndrome with basal ganglia lesion in neuromyelitis optica spectrum disorders. Neurocase, 2021, 27, 223-226.	0.2	3
96	A case of fulminant neuromyelitis optica presenting with destructive lesions in whole-brain. Clinical Neurology and Neurosurgery, 2014, 116, 87-89.	0.6	2
97	Efficacy and safety of dimethyl fumarate in treatment-naÃ ⁻ ve Japanese patients with multiple sclerosis: Interim analysis of the randomized placebo-controlled study. Multiple Sclerosis Journal - Experimental, Translational and Clinical, 2019, 5, 205521731985272.	0.5	2
98	Cryptococcal Meningitis in a Fingolimod-Treated Patient. Neurology: Clinical Practice, 2021, 11, e549-e550.	0.8	2
99	Upbeat nystagmus at caudal brainstem lesions in four cases with multiple sclerosis and its related disorders. Clinical and Experimental Neuroimmunology, 2013, 4, 206-209.	0.5	1
100	Autoimmune polyendocrine syndrome type 3 in a multiple sclerosis patient. Clinical and Experimental Neuroimmunology, 2015, 6, 299-303.	0.5	1
101	Anatomical connectivity elucidated by analysing thalamic atrophy in neuromyelitis optica. Journal of Neurology, Neurosurgery and Psychiatry, 2019, 90, 1075-1075.	0.9	1
102	Cognition with magnetic resonance imaging findings and social activities in patients with multiple sclerosis in a Japanese cohort. Clinical and Experimental Neuroimmunology, 2019, 10, 41-48.	0.5	1
103	Clinical difference after the first optic neuritis between aquaporin-4-IgG-associated and myelin oligodendrocyte glycoprotein-IgG-associated disorders. Journal of Neurology, 2021, , 1.	1.8	1
104	Remyelination and neuroprotective effects of alemtuzumab therapy in patients with multiple sclerosis. Journal of Neurology, Neurosurgery and Psychiatry, 2021, 92, 1251-1251.	0.9	1
105	Correlation of the symbol digit modalities test with the quality of life and depression in Japanese patients with multiple sclerosis. Multiple Sclerosis and Related Disorders, 2022, 57, 103427.	0.9	1
106	Low anti-CFL1 antibody with high anti-ACTB antibody is a poor prognostic factor in esophageal squamous cell carcinoma. Esophagus, 2022, 19, 617-625.	1.0	1
107	Guillain-Barré syndrome and influenza A (H1N1) 2009 monovalent inactivated vaccines: The risks and benefits. Clinical and Experimental Neuroimmunology, 2013, 4, 249-250.	0.5	0
108	Environment surrounding the ganglioside clusters as immunological targets in <scp>G</scp> uillain– <scp>B</scp> arré syndrome. Clinical and Experimental Neuroimmunology, 2013, 4, 10-11.	0.5	0

#	Article	IF	CITATIONS
109	Multiple enhancing brain lesions after discontinuation of fingolimod in a patient with multiple sclerosis. Clinical and Experimental Neuroimmunology, 2014, 5, 52-53.	0.5	Ο
110	A Case of Anti-aquaporin-4 Antibody-Seronegative NMO Spectrum Disorder with BalÃ ³ Concentric Lesions. Internal Medicine, 2014, 53, 531-531.	0.3	0
111	The role of granulocyteâ€macrophage colonyâ€stimulating factor in the pathogenesis of neuromyelitis optica: A white or black knight?. Clinical and Experimental Neuroimmunology, 2015, 6, 70-77.	0.5	Ο
112	Moesin, membraneâ€organizing extension spike protein, is a possible immunological target in Guillain–Barré syndrome after cytomegalovirus infection. Clinical and Experimental Neuroimmunology, 2015, 6, 5-6.	0.5	0
113	Geographical differences in preventative therapies for neuromyelitis optica spectrum disorder. Journal of Neurology, Neurosurgery and Psychiatry, 2017, 88, 620-620.	0.9	Ο
114	Insights from the differences in clinical profiles of neuroimmune disorders between patients in Japan and those in Western countries. Clinical and Experimental Neuroimmunology, 2021, 12, 146-147.	0.5	0
115	Methodology for identification of new target molecules in neuroimmunological disorders. Clinical and Experimental Neuroimmunology, 2021, 12, 202-207.	0.5	Ο
116	Severe orthostatic hypotension associated with lesions of the area postraema in neuromyelitis optica spectrum disorder. ENeurologicalSci, 2021, 23, 100335.	0.5	0
117	Cell-based flow cytometry assay for simultaneous detection of multiple autoantibodies in a single serum sample. Analytical Biochemistry, 2022, , 114721.	1.1	0